Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082719 · ClinicalTrials.gov registry record · Phase 1
Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00082719: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00082719 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00082719, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of urothelial cancer. PURPOSE: This randomized phase I trial is studying how well low-dose interferon alfa works in treating patients with cancer of the urothelium.
Interventions
- BIOLOGICAL Recombinant Interferon Alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2003-12 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082719
The ClinicalTrials.gov registry entry for NCT00082719 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant Interferon Alfa is the first listed.
NCT00082719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082719 about?
NCT00082719 is a clinical study titled "Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium". RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of urothelial cancer. PURPOSE: This randomized phase I trial is studying how well low-dose interferon alfa works in treating patients with cancer of the urothelium.
What is the current status of trial NCT00082719?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2003-12. Estimated completion is 2015-01.
What interventions are being tested in trial NCT00082719?
The interventions under investigation include: Recombinant Interferon Alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00082719?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.